GW's finance chief resigns
This article was originally published in Scrip
GW Pharmaceuticals announced that, after ten years as finance director, David Kirk has informed the company that he intends to stand down from the Board on 1 June 2012. Mr Kirk will be succeeded by Adam David George, who has served as GW’s company secretary and group financial controller since 2007. Mr Kirk will continue to be available to the company in a consulting capacity for an agreed period of time.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.